When topical Imiquimod was combined with intradermal administration of the NY-ESO-1 TSA to treat patients with malignant melanoma, NY-ESO-1 CD4+, but not CD8+, T cell responses were detected (82). This evidence concerns the gene CD8A and melanoma.